Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy

BACKGROUND: Sapanisertib, a dual mTORC1/2 inhibitor, may offer more complete inhibition of the PI3K/AKT/mTOR pathway than mTORC1 inhibitors, such as everolimus. This phase II study evaluated the efficacy and safety of single-agent sapanisertib and sapanisertib plus the PI3Kα inhibitor TAK-117, vs. e...

Descripción completa

Detalles Bibliográficos
Autores principales: Choueiri, Toni K, Porta, Camillo, Suárez, Cristina, Hainsworth, John, Voog, Eric, Duran, Ignacio, Reeves, James, Czaykowski, Piotr, Castellano, Daniel, Chen, Jingjing, Sedarati, Farhad, Powles, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732228/
https://www.ncbi.nlm.nih.gov/pubmed/36146944
http://dx.doi.org/10.1093/oncolo/oyac192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732228/
https://www.ncbi.nlm.nih.gov/pubmed/36146944
http://dx.doi.org/10.1093/oncolo/oyac192

Ejemplares similares